Talecris to price $550 million seven-year senior notes this week

By Paul A. Harris

St. Louis, Oct. 13 - Talecris Biotherapeutics Holdings Corp. plans to price a $550 million offering of seven-year senior notes late this week, according to an informed source.

Morgan Stanley, Goldman Sachs, Wells Fargo and Citigroup are joint bookrunners for the Rule 144A/Regulation S with registration rights offering.

The notes come with three years of call protection, however 10% of the principal may be redeemed each year for the first three years.

Credit ratings remain to be determined.

Proceeds will be used to refinance debt.

The prospective issuer is a Triangle Park, N.C., biotherapeutics company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.